spk8011 aav fviii phase 1/2 trial
Published 3 years ago • 45 plays • Length 5:01Download video MP4
Download video MP3
Similar videos
-
4:15
spk-8011: stable and durable fviii expression
-
0:49
bay 2599023 phase 1/2 trial
-
5:00
valoctocogene roxaparvovec aav gene transfer for severe hemophilia: results from phase 3 trial
-
27:06
update on phase i/ii clinical trial for ornithine transcarbamylase (otc) deficiency using aav
-
20:34
gene therapy for treatment of hemophilia: aav vector gene therapy application to hemophilia
-
17:48
life with hemophilia after gene therapy (from the peruvian amazon) | wfh2022 presentation
-
53:38
q & a session on pre clinical trial study of aav mediated gene therapy for dmd
-
34:50
gene therapy for hemophilia: progress and conundrums
-
3:08
aavantgarde bio’s dual-vector ush1b gene therapy moves into phase 1/2 clinical trial
-
4:39
a post hoc analysis of the gener8 1 phase 3 trial
-
0:44
current aav hemophilia b gene therapy trials
-
36:32
gene therapy for fviii
-
17:08
achievement of normal fviii activity following gene transfer with valoctocogene roxaparvovec…
-
1:02:04
multiyear factor viii expression after adeno‐associated virus gene transfer for hemophilia a
-
5:50
long-term vector genome outcomes and immunogenicity of aav fviii gene transfer in hemophilia a
-
5:23
long term expression of aav mediated fviii gene transfer and vector integration events
-
2:19
ongoing hemophilia a gene therapy trials
-
2:18
personalized fviii treatment for hemophilia a | bayer
-
2:59
spark therapeutics' pipeline overview
-
10:49
hemophilia a and immune response
-
6:21
dr. barbara konkle discusses the alta study